Bell Potter Report (inc SP valuation), page-2

This BP report interesting, just read it, in particular their “theoretical” commentary about future pivotal randomised control trial.
•OSL really needs to get a move on with this because it’s the one thing that (if positive result) could be game changer.
•imo They’ve taken much too long to decide what to do, they’ve had years to think about it and 6m ago they said they were discussing with fda
• i Thought whole point of being called breakthrough is fda helps with trial design and speed so really they should have a protocol by now but according to BP their CMO is still to work on it (didn’t know they have CMO?)
• BP says OSL hasn’t committed to trials so if that’s true why did OSL tell market during CR that ~50% was for US trials?